AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$PCVX

Vaxcyte GAAP EPS of -$1.99 beats by $0.15 (NASDAQ:PCVX)

Vaxcyte (PCVX) reported Q3 GAAP EPS of -$1.99, beating estimates by $0.15. The company had $2.26B in cash and investments as of September 30, 2026, down from $2.44B at the end of 2025, before a $1.1B offering in October 2026.

Original reporting
seekingalpha.com
Published Nov 4, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PCVX
Bullish
medium confidence
Mentioned
$PCVX
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PCVXBullishMed
01

Why it matters

The earnings beat provides a short‑term catalyst, but the company's cash burn and need for further financing temper upside.

02

Market read

Earnings beat may trigger a brief rally; investors should watch cash position and upcoming financing.

03

What to watch

Cash balance decline and upcoming capital raise could offset the earnings beat.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Vaxcyte (NASDAQ:PCVX) reported its Q3 2026 earnings, showing a GAAP EPS beat and a reduction in cash holdings after a recent offering.

Company-level read

Ticker impact

$PCVXBullishMedium confidence
Context

Q3 GAAP EPS of -$1.99 beats consensus by $0.15, disclosed in the press release.

Expected impact

likely modest upside as market prices in the beat

Evidence & confidence

The beat is a fresh earnings disclosure for a small-cap biotech; such news typically yields a short-term price lift.

Market effects

Sector

May improve sentiment for the biotech sector as earnings beat signals progress.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to the company and its niche sector.

Counterpoint

What could challenge this read

The beat is modest and the company remains cash‑burning; price may not sustain.

Key entities

  • Company
    Vaxcyte

    Biotech firm listed on NASDAQ under PCVX.

Read at source← All news

Related articles

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

SEC EDGAR 8-K
$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.

stocktitan.net
$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.

globenewswire.com